The Ozempic from Novo Nordisk A/ S - weekly injection that reshaped diabetes care

Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-28, 08:05. Details in the imprint.

The Ozempic pen rests cold against the skin for a second before the quiet click, a routine many people with type 2 diabetes now know by heart. Once a week, one injection of semaglutide replaces the daily pill carousel and some multiple insulin shots.

How Ozempic works week by week

Ozempic from Novo Nordisk is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist based on semaglutide for adults with type 2 diabetes. It is approved to improve glycaemic control and, in certain regions, to reduce cardiovascular risk in patients with established cardiovascular disease.

By mimicking the GLP-1 hormone, semaglutide increases insulin secretion when blood sugar is high, reduces glucagon, slows gastric emptying and helps patients feel fuller after meals. In the SUSTAIN clinical program, once-weekly semaglutide showed significant reductions in HbA1c and body weight compared with several existing treatments.

What patients see in daily life

In practical terms, a typical Ozempic start involves titrating from 0.25 mg to 0.5 mg once weekly, with some patients later moving to 1 mg or higher strengths depending on local approvals and clinical need. The disposable pre-filled pens are designed for simple one-step needle attachment and dose selection, something diabetes nurse educator Anne Sørensen repeatedly demonstrates during training sessions in Copenhagen clinics.

Many users report a quieter glucose curve across the day and a more consistent morning reading on their home meters once the dose is stable. Common adverse reactions include nausea, vomiting and diarrhea, particularly in the first weeks, which clinicians manage by slow dose escalation and food counselling.

The data behind the hype

Chief scientific officer Marcus Schindler regularly highlights the SUSTAIN 6 cardiovascular outcomes trial, where semaglutide showed a significant reduction in major adverse cardiovascular events versus placebo in high-risk type 2 diabetes patients. That result helped differentiate Ozempic from pure glucose-lowering competitors and underpins parts of its label in Europe and the US.

In several head-to-head studies, weekly semaglutide provided greater HbA1c reductions and weight loss than once-daily liraglutide and some basal insulins, while maintaining a comparatively low risk of hypoglycaemia when used without sulfonylureas. Regulators have nevertheless flagged the class risk of thyroid C-cell tumors seen in rodent models, so Ozempic carries a contraindication for patients with a personal or family history of medullary thyroid carcinoma.

Pen design and handling

The Ozempic pen uses a non-reusable, pre-filled format with a built-in dose selection dial and an injection button that offers clear tactile feedback under the thumb. Patients often mention the smooth rotation of the dial and the audible clicks as reassurance that the correct dose is set before injection.

For storage, the pens stay refrigerated before first use and can then be kept at room temperature for a limited period, which suits people who travel or carry the pen in a laptop bag during the week. Needles are disposed of in dedicated sharps containers, a detail diabetes teams repeat in training sessions to avoid improvised home solutions.

Where Ozempic fits in therapy

Guidelines in Europe and North America now position GLP-1 therapies such as Ozempic ahead of insulin for many patients whose blood sugar is not controlled with metformin and lifestyle change alone. Primary care physicians and endocrinologists often combine weekly semaglutide with metformin or SGLT2 inhibitors to address both glycaemic control and cardiorenal risk.

In obesity, semaglutide has a separate high-dose brand, Wegovy, but some real-world data sets still track weight trends in Ozempic users who receive the lower diabetes dosing. Novo Nordisk stresses that Ozempic is indicated for diabetes and cardiovascular risk reduction, not for cosmetic weight management, in its professional materials.

Pricing, access and demand

List prices for Ozempic vary strongly by market and insurance system, but the product is generally reimbursed in major European countries and the US when prescribed for approved indications. Health systems negotiate discounts, and many patients face co-pays that depend on local formularies and income-based schemes.

The surge in global demand for GLP-1 drugs has strained manufacturing capacity at times, forcing Novo Nordisk to expand production sites in Kalundborg and other locations to stabilise supply. Hospital pharmacist Lars Jensen in Aarhus notes that, compared with early 2023, weekly stock-outs have become rarer but still occur for certain strengths.

Regulation and safety signals

Ozempic’s label includes warnings on pancreatitis, diabetic retinopathy complications and potential gallbladder disease, reflecting signals from clinical trials and post-marketing surveillance. Doctors monitor patients with a history of pancreatitis closely and advise them to seek immediate care if they experience persistent severe abdominal pain.

European and US regulators have also looked at reports of suicidal ideation with GLP-1 drugs, though a causal link has not been established and investigations remain ongoing. Novo Nordisk reports adverse events systematically and updates healthcare professionals through periodic safety communications when new data emerge.

Investor angle on a classic

Ozempic sits alongside Rybelsus and Wegovy in Novo Nordisk’s semaglutide franchise and remains a core earnings driver in diabetes even as obesity therapies take more headlines. The product’s long-running data set and broad guideline support give it a relatively stable role in treatment algorithms.

Novo Nordisk shares (ISIN DK0060534915) trade on Nasdaq Copenhagen, with investors watching weekly GLP-1 prescription trends and capacity expansion updates as key indicators for the medium-term outlook.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.